Systolic function and left ventricular mass
At baseline, mean LVEF was 59.0% (8.0), with 86% of the population having an LVEF above 50%. Following the addition of eplerenone, neither EDV nor ESV changed from baseline in either group or when comparing groups at week 26. There was no change in LVEF when comparing groups at week 26 (0.9, 95%CI [-1.1 to 2.8], Evaluating additional measures of left ventricular function obtained using a conventional echocardiography protocol, we observed no significant effect of treatment when comparing groups at 26 weeks (Supplementary table 